



**ASX Announcement
16 December 2020**

Appointment of Taiwan Distributor

Highlights

- **Appointment of J&H Technology Co Ltd as Optiscan’s exclusive pre-clinical distributor for Taiwan**
- **J&H Technology is a distributor of leading United States and European pre-clinical equipment**

Optiscan Imaging Limited (ASX: OIL) (‘the Company’ or ‘Optiscan’) announces that it has appointed J&H Technology as its exclusive distributor in Taiwan for the FIVE2 (ViewnVivo) in the pre-clinical research market. This appointment follows the appointment of two (2) China distributors in Shanghai and Guangzhou in 2019 and a new distributor in North America in 2020. Taiwan represents an attractive market for the FIVE2 (ViewnVivo), being consistently ranked as the top knowledge economy in Asia, with its biomedical sector identified as one of the five pillar industries for its national development.

J&H Technology was founded in 2000 and has approximately 25 staff. It is a distributor for leading United States and European pre-clinical suppliers including ThermoFisher Scientific, PerkinElmer and Miltenyi Biotec.

Optiscan’s Executive Chairman Darren Lurie, said:

“The appointment of J&H Technology continues the expansion of our international distribution arrangements for the FIVE2 (ViewnVivo) in the pre-clinical research market. We are very pleased to have such a well-credentialed partner in an attractive market.”

- ends -

This announcement has been authorised for release by the Board of OIL.

For investor queries, please contact:

Darren Lurie
CEO and Executive Chairman – Optiscan Imaging Limited
E: dlurie@optiscan.com

Phone (61 3) 9538 3333

Website www.optiscan.com

PO Box 1066, Mt Waverley MDC VIC 3149 Australia

About Optiscan

Optiscan is a global leader in the development of microscopic imaging and related technologies for screening, surgery and medical research. Based in Melbourne, Australia, Optiscan has developed and patented endomicroscopic technology which enables real-time, 3D, 'in vivo' imaging of human tissue at the cellular level – instant “virtual biopsies” with applications for cancer screening and surgical margin determination. Optiscan’s technology has the capability to improve patient welfare, reduce hospital costs, improve accuracy and reduce the need for multiple procedures. The technology is approved for use in brain surgery and is involved in a number of oral cancer and breast cancer studies.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate’, ‘believe’, ‘could’, ‘estimate’, ‘expect’, ‘future’, ‘intend’, ‘may’, ‘opportunity’, ‘plan’, ‘potential’, ‘project’, ‘seek’, ‘will’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

Phone (61 3) 9538 3333

Website www.optiscan.com

PO Box 1066, Mt Waverley MDC VIC 3149 Australia